(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 88.68% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Insmed's revenue in 2026 is $606,423,000.On average, 24 Wall Street analysts forecast INSM's revenue for 2026 to be $369,024,845,952, with the lowest INSM revenue forecast at $204,692,391,480, and the highest INSM revenue forecast at $499,649,294,928. On average, 23 Wall Street analysts forecast INSM's revenue for 2027 to be $609,580,761,888, with the lowest INSM revenue forecast at $409,979,706,192, and the highest INSM revenue forecast at $813,277,303,608.
In 2028, INSM is forecast to generate $884,193,877,392 in revenue, with the lowest revenue forecast at $691,706,034,264 and the highest revenue forecast at $1,156,220,370,144.